• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Business Directory
    • Buyers | Licensees
    • Sellers | Ancillary Businesses
    • Submit Product & Service Press Release
  • CBE Exchange
  • CBE Jobs Exchange
  • Events
  • Featured Videos
  • Product & Service Press Releases
  • Sponsored Polls
  • Webinars
    • Upcoming Webinars
    • Archived Webinars
  • Whitepapers

Cannabis Business Executive - Cannabis and Marijuana industry news

Recreational, Medical, Marijuana, Cannabis, And Hemp News for Cannabis Businesses

  • Follow on Facebook
  • Follow on Twitter
  • Follow on Google+
  • Follow on LinkedIn
  • Subscribe to our RSS feed
Newsletter 2
  • Home
  • Policy & Legal
    • Hemp Business Executive
    • International
      • Canada
      • Mexico
      • Israel
    • US A to F
      • Alabama
      • Alaska
      • Arizona
      • Arkansas
      • California
      • Colorado
      • Connecticut
      • Delaware
      • District of Columbia
      • Florida
    • US G to M
      • Georgia
      • Hawaii
      • Illinois
      • Indiana
      • Idaho
      • Iowa
      • Kansas
      • Kentucky
      • Louisiana
      • Maine
      • Maryland
      • Massachusetts
    • US M to N
      • Michigan
      • Minnesota
      • Mississippi
      • Missouri
      • Montana
      • Nebraska
      • Nevada
      • New Hampshire
      • New Jersey
      • New Mexico
      • New York
      • North Carolina
      • North Dakota
    • US O to V
      • Ohio
      • Oklahoma
      • Oregon
      • Pennsylvania
      • Rhode Island
      • South Carolina
      • South Dakota
      • Tennessee
      • Texas
      • Utah
      • Vermont
    • US V to W
      • Virginia
      • Washington
      • Wisconsin
      • Wyoming
      • Guam
      • Puerto Rico
  • Industry News
    • Advertising, Marketing, PR & Research
    • Banking, Finance & Real Estate
    • Compliance and Regulations
    • Corporate Social Responsibility
    • Retailers
    • Hemp Business Executive
    • HR and Staffing
    • North Of The Border
    • Industry People/On the Move
    • Packaging and Supplies
    • Press Releases
    • Processors
    • Producers
    • Security Solutions
    • Science and Technology
    • South Of The Border
  • CBE Lists
    • Ancillary Businesses
      • 2019 CBE Ancillary Business Survey CLICK HERE
      • 2018 CBE 155 A/B
      • 2017 CBE 150 A/B
      • 2016 CBE 100 A/B
    • Producers, Processors, Retailers
      • 2017 CBE 200 PPRs
      • 2015 CBE 100 PPRs
    • Industry Women
      • Glass Ceiling Wreckers: 2019 CBE Power Women of Cannabis
      • 2017 CBE 75 Most Important Women
      • 2016 CBE Top 50 Women
      • 2014 CBE Most Influential Women
    • Most Important Companies
      • 2016 CBE 10 Most Important Companies
      • 2014 CBE 10 Most Important Companies
    • Political 100
      • 2017 CBE Political 100
      • 2016 CBE 100 Political
      • 2014 CBE Political 50
    • 2014 CBE 100 Most Important People
    • CBE RFP Hotlists
      • 2014 CBE Lab Testing Services HotList
      • 2016 BHO Extraction Equipment
      • 2016 CBE Supercritical CO2 Extraction Equipment
      • 2016 CBE Security Solutions
      • 2016 Edibles & Infused Products
  • Company Stories
    • Up and Comers
  • Hemp Business Executive
    • Hemp Policy & Legal
    • Hemp Industry News
    • Hemp State Regulatory Agencies
  • Newsletters
    • CBE Week
    • CBE Human Capital Management
    • CBE Technology & Solutions
    • CBE Policy and Legal Update
    • CBE Product and Service Announcements
  • Op-Ed
    • Cartoons
    • The Buck Stops Here
    • Opinions
    • Comments
  • Associations
  • State Regulatory Agencies
    • Marijuana
    • Hemp
  • Contact
  • AB Survey
  • About Us
  • Account
  • Accounting Services
  • Advertise
  • Advertising, PR & Marketing
  • All Cannabis News
  • Ancillary Business Survey 2018
  • Ancillary Business Survey 2019
  • Archived Webinars
  • Associations & Organizations
  • Banking & Payment Processing
  • Better Start for the Glass Ceiling in this Industry, CBE’s Most Influential Women
  • Book Reviews
  • Business Directory
  • Business Directory Introduction
  • Business Directory Listing
  • Business Directory Manage
  • Business Directory Registration Info
  • Business Directory Welcome
  • Call for speakers
  • Cannabis Investments
  • Cart
  • CBE Exchange
  • CBE HotLists
    • CBE Lab Testing Services HotList 2014
  • CBE Lists
  • CBE Political 50
  • CBE Press LLC Privacy Statement
  • CBE Press News
  • Checkout
  • Consulting Services
  • Consumption Gear
  • Contact
  • Contribute
  • Contributors
  • Create Your Product & Service Press Release
  • Creative Submission
  • Cultivation Products & Services
  • Current Poll
  • Edible & Infused Products
  • Editor’s Page
  • Email Whitelisting Instructions
  • Event Listing Questionaire
  • Featured Videos
  • Funding Options
  • Hemp State Regulatory List
  • Home
  • Human Capital Management Newsletters
  • Industry Jobs
  • Join the CBE Business Directory
  • Join the Directory
  • Lab Testing Regulations
  • Lab Testing Services
  • Login
  • Logout
  • Marijuana State Regulatory Contacts
  • Marijuana Tax Facts
  • Media Kit
  • Medical Marijuana Qualifying Conditions
  • Members
  • MJ Media Kit
  • Most Popular Stories
  • Most Read Stories
  • New Product & Service Listings Welcome
  • News Releases
  • Newsletters
    • Ask CBE
    • CBE Human Capital Management
    • CBE Policy and Legal Update
    • CBE Product and Service Announcements
    • CBE Technology & Solutions
    • CBE Week
  • On the Move
  • Organizations & Associations
  • Packaging & Supplies
  • Password Reset
  • Policy & Legal
  • PPR Survey
  • Product Releases
  • Profile Update
  • Register
  • Security Solutions
  • Software & Technology
  • Sponsored Polls
  • State Cannabis Product Packaging Requirements
  • Terms of Service
  • Thank You
  • The Most Influential People in the Cannabis Industry, The Cannabis Business Executive 100
  • Training & Educational Services
  • Upcoming Webinars
  • User
  • Whitepapers
  • WV Senate passes medical marijuana bill to House
  • Categories
  • Locations
  • My Bookings
You are here: Home / Policy & Legal / FDA Updates Guidance for CBD Products amid a New Round of Warning Letters and Announcement of Date for Public Hearing

FDA Updates Guidance for CBD Products amid a New Round of Warning Letters and Announcement of Date for Public Hearing

April 3, 2019 by Ian Stewart Leave a Comment

By Ian Stewart & Neil Willner Attorneys at Wilson Elser

On April 2, 2019, the U.S. Food and Drug Administration (FDA) issued a sweeping press release from outgoing Commissioner Scott Gottlieb covering new steps to advance the agency’s continued evaluation of potential regulatory pathways for CBD products. The five-page statement outlined what the FDA has in store for the industry over the next several months. Among other things, the FDA has:

  • Scheduled a public hearing for May 31 to allow stakeholders to share experiences and challenges with CBD products, including opinions on public safety concerns.
  • Announced formation of an internal agency working group to “explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed.”
  • Overhauled its FAQ webpage, providing answers and new guidance for CBD products, including cosmetics.
  • Issued three warning letters to companies marketing CBD products using “egregious and unfounded claims aimed at vulnerable populations.” 

In the press release, Gottlieb reinforced the FDA’s position that it is unlawful to introduce food with added CBD or THC into interstate commerce, or to market CBD and THC dietary supplements. While the availability of CBD products has dramatically increased over the past several years, many unanswered questions and potential health risks remain, according to the FDA. Chief among these are the potential for liver injury and cumulative exposure to CBD if accessed by consumers across a range of products. 

The FDA is concerned that permitting widespread commercial availability of CBD products negatively impacts research may otherwise be performed to support regulatory approval through the FDA’s drug review process. Similarly, the FDA does not want to incentivize patients to forgo appropriate medical treatment by substituting unapproved products for FDA-approved medicines.

Several large national retailers recently announced they will begin selling CBD-infused products. Shortly after the press release, Commissioner Gottlieb addressed his concerns, tweeting “I was also concerned to hear recently that several national pharmacy chains and other major retailers have begun to sell or will soon begin to sell CBD products in several states. We’ll be contacting them to remind them of FDA obligations and our commitment to protect consumers against products that can put them at risk.” 

Warning Letters – Updated Guidance for the Industry

Consistent with the FDA’s public health concerns, Gottlieb announced that the agency, in collaboration with the Federal Trade Commission (FTC), has issued a new round of warning letters to three companies that have made “egregious claims about their products’ ability to limit, treat or cure cancer, neurodegenerative conditions, autoimmune disease, opioid disorder, and other serious diseases, without sufficient evidence and the legally required FDA approval.” Gottlieb made clear that these “egregious, over-the-line claims won’t be tolerated.” Because the three companies claim that their CBD products were intended to diagnose, cure, mitigate, treat or prevent disease, the FDA considered them a drug that may not be introduced into interstate commerce without prior approval. 

For the first time, the FDA also has scrutinized the nutrition fact panels on CBD products, warning that, to the extent the product label suggests it is food, it is unlawful to introduce any food into interstate commerce to which CBD has been added. 

The most recent round of warning letters also includes another first; a warning from the FTC that  it is unlawful under the FTC Act to advertise that a CBD product can prevent, treat or cure disease unless the company has competent and reliable scientific evidence backing up its claims. 

The FDA Breaks Its Silence on CBD-Infused Cosmetics in Overhauled FAQ 

Since cosmetics are less heavily regulated by the FDA than food and drugs, the agency has remained largely silent on the use of CBD in cosmetics products − until now. In its FAQ, the FDA provided much-needed insight, stating that “cannabis or cannabis-derived ingredients” are not necessarily prohibited ingredients in cosmetics products and affirmed that these ingredients are not specifically addressed by regulation. However, the FDA warned that no ingredient − including cannabis-derived ingredients – can be used in a cosmetic if “it causes the product to be adultered or misbranded.” 

The FAQ also is replete with examples of the Agency’s concern over deceptive marketing tactics for unproven health claims. The FDA explained that these practices raise significant public health concerns because “patients and other consumers may be influenced not to use approved therapies to treat serious diseases.” 

The FDA also briefly touches on THC products and state-sanctioned medical marijuana programs. In response to what is the FDA’s reaction to states that allow cannabis to be sold for medical uses without the FDA’s approval, the FDA stressed the importance of medical research and welcomed the opportunity to talk with states that are considering support for medical research of cannabis-derived medicine. 

The FDA’s Notice for Public Hearing

The FDA announced that it is holding a public hearing on May 31, 2019, given the substantial interest in CBD-infused products and congressional interest in fostering development of appropriate hemp products under the 2018 Farm Bill, while preserving the FDA’s ability to protect public health. The anticipated goal of the hearing is to “obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, from both botanical and synthetic sources, to inform FDA’s regulatory oversight of these products.” 

The hearing will cover a range of CBD-related topics, including (1) Health and Safety, (2) Manufacturing and Product Quality and (3) Marketing/Labeling/Sales. The FDA is encouraging public comments and participation at the hearing. 

Additional information can be found at www.wilsonelser.com/cannabis.

Filed Under: Policy & Legal, Spotlight Tagged With: Federal Trade Commission (FTC), Hemp-CBD, interstate commerce, public hearing, Scott Gottlieb, U.S. Food and Drug Administration (FDA)

About Ian Stewart

Ian is a partner in the Los Angeles office of Wilson Elser. He is co-founder and chair of the Wilson Elser Cannabis Law practice and uses his 20 years of legal experience to help clients navigate the legalities around cannabis and hemp. Ian works with licensed cannabis operators to comply with their obligations under the law and to develop risk management best practices. He also regularly consults with insurance companies to assist with cannabis-related underwriting practices and the development of new policy forms.

He is currently Chair of the National Cannabis Industry Association’s Finance and Insurance Committee, as well as Vice-Chair of the California Cannabis Industry Association’s Insurance Committee. Ian received his B.A. from Washington University in St. Louis, and his JD from St. Louis University. He has been with Wilson Elser for the past 18 years.

Primary Sidebar

Ad: Sidebar 1

Featured Video

Associations & Organizations

clearing div

Ad: Sidebar 2

Business Directory

Ad: Skyscraper 1

CBE Jobs Exchange


Featured Jobs
Go
Post a Job
More jobs
Powered by CBEJobsExchange.com

RSS Recent Jobs

  • Alcohol and Other Drug Health Promotion Coordinator - Central Washington University - Ellensburg, WA
  • Hearing Officers (Apply by Feb. 5th) - The Broward County Attorney's Office - Fort Lauderdale, FL
  • Field Service Engineer Agilent GC/MS - VRS Recruitment - , MA

Product & Service Press Releases

Ad: Sidebar 3

CBE Events

Ad: Sidebar 4

State Regulatory Agencies

Ad: Skyscraper 2

Webinars

Ad: Sidebar 5

Associations & Organizations

Ad: Sidebar 6

Featured Video

Ad: Skyscraper 3

Business Directory

Ad: Sidebar 7

CBE Jobs Exchange

Ad: Sidebar 8

CBE Events

Ad: Skyscraper 4

Industry Blogs



Footer

  • Home
  • About Us
  • Advertise
  • Contact
  • CBE Press LLC Privacy Statement
  • Contribute
  • Contributors
  • Newsletters
  • Terms of Service
  • Contributor Login
  • Follow on Facebook
  • Follow on Twitter
  • Follow on Google+
  • Follow on LinkedIn
  • Subscribe to our RSS feed
Newsletter 2

© Copyright 2020 CBE PRESS LLC. - All Rights Reserved. Cannabis Business Executive Is A Trademark Of CBE PRESS LLC. · All Rights Reserved · And Our Sitemap · All Logos & Trademarks Belong To Their Respective Owners·